In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Symphony Neuro licenses Guilford's GPI 1485

Executive Summary

Symphony Neuro Development, a financing and clinical development structure, has been set up by VC company Symphony Capital in order to license exclusive US rights to Guilford Pharmaceuticals' neuroimmunophilin ligand GPI 1485 for Parkinson's disease and post-prostatectomy erectile dysfunction (in Phase II for both indications) and HIV-related dementia and neuropathy (both preclinical).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies